Compare Eiken Chemical Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 88,495 Million (Small Cap)
23.00
NA
0.00%
-0.10
8.42%
2.01
Revenue and Profits:
Net Sales:
10,728 Million
(Quarterly Results - Jun 2026)
Net Profit:
445 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.82%
0%
-27.82%
6 Months
-10.06%
0%
-10.06%
1 Year
-2.03%
0%
-2.03%
2 Years
4.82%
0%
4.82%
3 Years
52.3%
0%
52.3%
4 Years
18.38%
0%
18.38%
5 Years
0.09%
0%
0.09%
Eiken Chemical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.15%
EBIT Growth (5y)
-11.55%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.84
Tax Ratio
23.27%
Dividend Payout Ratio
51.56%
Pledged Shares
0
Institutional Holding
0.35%
ROCE (avg)
14.52%
ROE (avg)
9.70%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.10
EV to EBIT
28.28
EV to EBITDA
15.68
EV to Capital Employed
2.18
EV to Sales
2.15
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
7.70%
ROE (Latest)
9.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.35%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
10,728.00
10,522.00
1.96%
Operating Profit (PBDIT) excl Other Income
1,274.00
846.00
50.59%
Interest
19.00
15.00
26.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
445.00
-14.00
3,278.57%
Operating Profit Margin (Excl OI)
62.30%
13.40%
4.89%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 1.96% vs -3.88% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 3,278.57% vs -101.88% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
41,899.00
40,539.00
3.35%
Operating Profit (PBDIT) excl Other Income
5,457.00
5,554.00
-1.75%
Interest
29.00
17.00
70.59%
Exceptional Items
0.00
-250.00
100.00%
Consolidate Net Profit
3,708.00
2,228.00
66.43%
Operating Profit Margin (Excl OI)
69.70%
74.00%
-0.43%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 3.35% vs 1.22% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 66.43% vs -15.41% in Mar 2025
About Eiken Chemical Co., Ltd. 
Eiken Chemical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






